{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:50:09Z","timestamp":1782121809998,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sunshine Guojian Pharmaceutical Co. Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,12,6]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While anti-vascular endothelial growth factor (VEGF) therapies are effective for macular oedema secondary to retinal vein occlusion (RVO), there remains a need for additional treatment options. This study evaluated the novel anti-VEGF agent 601 versus ranibizumab in patients with branch RVO (BRVO) or central RVO (CRVO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In two multicentre, randomised, double-masked, active-controlled phase IIa trials (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04667897\">NCT04667897<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04667910\">NCT04667910<\/jats:ext-link>\n                      ) conducted at 12 Chinese sites (2021\u20132022), 120 patients were assigned 1:1 to receive intravitreal 1.25\u2009mg 601 or 0.5\u2009mg ranibizumab every 4 weeks until week 20, followed by pro re nata dosing through week 48. Eligible patients had best-corrected visual acuity (BCVA) of 78\u201319 Early Treatment Diabetic Retinopathy Study letters and central subfield thickness \u2265250\u2009\u00b5m. The primary endpoint was change in BCVA at week 24.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 24, the adjusted mean BCVA change from baseline was +16.52 letters for 601 versus +17.79 letters for ranibizumab (adjusted mean difference: \u22121.27 letters (95%\u2009CI \u22125.439 to 2.891 letters)) in BRVO, and +13.81 letters versus +16.79 letters (adjusted mean difference: \u22122.97 letters (95%\u2009CI \u221210.488 to 4.540 letters)) in CRVO. Central retina thickness (CST) reduction was similar for both treatments. Both groups showed sustained improvements from week 24 to 52 with similar adverse event profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These trials demonstrate that 601 is as effective and safe as ranibizumab for improving vision and reducing CST in RVO-related macular oedema. Phase III trials are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-327845","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T18:20:17Z","timestamp":1766686817000},"page":"809-816","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials"],"prefix":"10.1136","volume":"110","clinical-trial-number":[{"clinical-trial-number":"nct04667897","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04667910","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04667897","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04667910","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shuo","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoqin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Zhejiang Provincial People\u2019s Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jinan University First Affiliated Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongming","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, People\u2019s Hospital of Henan University, Henan Provincial People's Hospital, Henan Eye Hospital, Henan Key Laboratory of Ophthalmology, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3502-9607","authenticated-orcid":false,"given":"Quanhong","family":"Han","sequence":"additional","affiliation":[{"name":"Tianjin Eye Hospital, Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Eye Diseases, Shanghai Clinical Research Center for Eye Diseases, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Eye Diseases, Shanghai Clinical Research Center for Eye Diseases, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-5394","authenticated-orcid":false,"given":"Jin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People\u2019s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Southwest Hospital of AMU, Chongqing, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Xi\u2019an Jiaotong University Second Affiliated Hospital, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lou","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical Shanghai Co Ltd, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Liu","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical Shanghai Co Ltd, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haomin","family":"Huang","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical Shanghai Co Ltd, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical Shanghai Co Ltd, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Xu","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical Shanghai Co Ltd, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2797","authenticated-orcid":false,"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"2026062202151378000_110.7.809.1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye (Lond)"},{"key":"2026062202151378000_110.7.809.2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/APO.0000000000000598","article-title":"Update on Retinal Vein Occlusion","volume":"12","author":"Romano","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026062202151378000_110.7.809.3","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.010427","article-title":"Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors","volume":"9","author":"Song","year":"2019","journal-title":"J Glob Health"},{"key":"2026062202151378000_110.7.809.4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"2026062202151378000_110.7.809.5","doi-asserted-by":"publisher","DOI":"10.1159\/000502041"},{"key":"2026062202151378000_110.7.809.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31559-2"},{"key":"2026062202151378000_110.7.809.7","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S7631"},{"key":"2026062202151378000_110.7.809.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"2026062202151378000_110.7.809.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.056"},{"key":"2026062202151378000_110.7.809.10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ajo.2005.03.003","article-title":"Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6","volume":"140","author":"Noma","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"2026062202151378000_110.7.809.11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1573399811666150615151324","article-title":"Anti-VEGF Therapy for Retinal Vein Occlusions","volume":"17","author":"Campa","year":"2016","journal-title":"Curr Drug Targets"},{"key":"2026062202151378000_110.7.809.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100921"},{"key":"2026062202151378000_110.7.809.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.021"},{"key":"2026062202151378000_110.7.809.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.022"},{"key":"2026062202151378000_110.7.809.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"2026062202151378000_110.7.809.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"2026062202151378000_110.7.809.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.031"},{"key":"2026062202151378000_110.7.809.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.035"},{"key":"2026062202151378000_110.7.809.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.01.042"},{"key":"2026062202151378000_110.7.809.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"2026062202151378000_110.7.809.21","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"key":"2026062202151378000_110.7.809.22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","article-title":"Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial","volume":"4","author":"Vader","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"2026062202151378000_110.7.809.23","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.36474"},{"key":"2026062202151378000_110.7.809.24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2026062202151378000_110.7.809.25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00417-019-04569-8","article-title":"Off-label use of bevacizumab for wet age-related macular degeneration in Europe","volume":"258","author":"Bro","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026062202151378000_110.7.809.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.005"},{"key":"2026062202151378000_110.7.809.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.012"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-327845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:16:38Z","timestamp":1782119798000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-327845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bjo-2025-327845"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-327845","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}